Triple Negative Breast Cancer: Worse or Just Different?

['lizbeth]

Thank you GDP for answering my question: What's next.

I am very excited about the upcoming ASCO conference in Chicago. I know one study I participated in is about to share some exciting news. Another will likely have good news for the SABCS.

It seems we need new lingo. The days of ER +/-, PR +/-, Her2 +/- are about to be left behind. Triple Positive, Triple Negative are too simple with cancer.

I can't believe there are women with lower expressions of Her2 who could have benefited from Herceptin. Yet with the current system it is a decade past the original FDA approval and these women are still grouped in the Triple Negative category, progressing and dying.

Thanks heavens for Research Rebels like Nagourney.